Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market - Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market -...

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsy Third FDA Breakthrough Therapy designation...

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...